<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671539</url>
  </required_header>
  <id_info>
    <org_study_id>THOR-TUE-01</org_study_id>
    <nct_id>NCT02671539</nct_id>
  </id_info>
  <brief_title>THOR - T端bingen Choroideremia Gene Therapy Trial</brief_title>
  <acronym>THOR</acronym>
  <official_title>THOR - T端bingen Choroideremia Gene Therapy Trial Open Label Phase 2 Clinical Trial Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>STZ eyetrial</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>STZ eyetrial</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label monocentric phase II trial in adult males with a clinical phenotype of&#xD;
      choroideremia and a confirmed molecular diagnosis of a null mutation in the gene encoding&#xD;
      REP1 to assess the anatomical and functional outcomes, as well as the safety of a single&#xD;
      subretinal injection of rAAV2.REP1 in 6 subjects with genetically confirmed choroideremia for&#xD;
      up to 24 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study name: THOR - T端bingen Choroideremia gene therapy trial open label Phase 2 clinical&#xD;
      trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1)&#xD;
&#xD;
      Phase: Phase II&#xD;
&#xD;
      Indication: Adult males with a clinical phenotype of choroideremia and a confirmed molecular&#xD;
      diagnosis of a null mutation in the gene encoding REP1&#xD;
&#xD;
      Aim of study: To assess the anatomical and functional outcomes, as well as the safety of a&#xD;
      single subretinal injection of rAAV2.REP1 in subjects with genetically confirmed&#xD;
      choroideremia for up to 24 months.&#xD;
&#xD;
      Primary Endpoint: Change from baseline in best corrected visual acuity in treated eye,&#xD;
      compared to untreated control eye&#xD;
&#xD;
      Study design: Open label monocenter study&#xD;
&#xD;
      Study population: 6 male adults affected by choroideremia&#xD;
&#xD;
      Inclusion Criteria&#xD;
&#xD;
        1. Participant is willing and able to give informed consent for participation in the study.&#xD;
&#xD;
        2. Male aged 18 years or above.&#xD;
&#xD;
        3. Genetically confirmed diagnosis of choroideremia. Patients without a confirmed mutation&#xD;
           in the CHM gene, but who have the clinical phenotype typical of choroideremia can only&#xD;
           be enrolled if they meet all the following three criteria: (i) family history consistent&#xD;
           with X-linked inheritance, (ii) absent REP1 protein on Western blot of a blood sample&#xD;
           and, (iii) normal RPE65 gene on sequencing.&#xD;
&#xD;
        4. Active disease visible clinically within the macula region&#xD;
&#xD;
        5. Best-corrected visual acuity equal to or worse than 6/9 (20/32; Decimal 0.63; LogMAR&#xD;
           0.2) but better than or equal to 6/60 (20/200; Decimal 0.1; LogMAR 1.0) in the study&#xD;
           eye.&#xD;
&#xD;
      Exclusion Criteria&#xD;
&#xD;
        1. Female and child participants (under the age of 18)&#xD;
&#xD;
        2. Participants with a history of amblyopia in the study eye&#xD;
&#xD;
        3. Men unwilling to use barrier contraception methods, if relevant&#xD;
&#xD;
        4. Absence of quantifiable visual function in the fellow eye or other ocular morbidity&#xD;
           which might confound use of the fellow eye as a long-term control.&#xD;
&#xD;
        5. Any other significant ocular and non-ocular disease/disorder or retinal surgery which,&#xD;
           in the opinion of the Investigator, may either put the participants at risk because of&#xD;
           participation in the study, or may influence the results of the study, or the&#xD;
           participant's ability to participate in the study. This would include not taking or&#xD;
           having a contraindication to oral prednisolone, such as a history of gastric ulcer or&#xD;
           significant side effects.&#xD;
&#xD;
        6. Participants who have participated in another research study involving an&#xD;
           investigational product in the past 12 weeks, or having had gene or cellular therapy at&#xD;
           any time prior to this study.&#xD;
&#xD;
        7. Patients with amblyopic eyes should be excluded in general, since the evaluation of the&#xD;
           primary endpoint presupposes the ability to fixate both eyes&#xD;
&#xD;
        8. Prior intraocular surgery within six months&#xD;
&#xD;
        9. Intolerance to local anesthesia and/or contraindication to IVT surgery (anemia Hb&lt;8g/dl,&#xD;
           severe cardiovascular disease, severe coagulopathy, etc.)&#xD;
&#xD;
       10. High fever or high fever disease, patients with a history of autoimmune conditions/&#xD;
           other systemic diseases that may have ocular manifestations (e.g. sarcoidosis) or&#xD;
           neurodegenerative conditions (e.g. multiple sclerosis, neuromyelitis optica, Parkinson's&#xD;
           disease)&#xD;
&#xD;
       11. Patients suffering from other genetic mutations leading to pathological retinal&#xD;
           conditions&#xD;
&#xD;
       12. Patients treated by oral corticoids within 14 days prior inclusion at the study entry&#xD;
&#xD;
      Patient number: 6&#xD;
&#xD;
      Treatment: Each participant will receive a single treatment of the rAAV2.REP1 vector (0.1ml&#xD;
      containing 1011 AAV2 genome particles) administered by subretinal injection during a&#xD;
      vitrectomy operation. No placebo will be used. ln order to minimize selection bias both eyes&#xD;
      are randomized to either treatment or control.&#xD;
&#xD;
      Main criteria: Primary endpoint: Change from baseline in best corrected visual acuity in&#xD;
      treated eye, compared to untreated control eye up to 24 months after vector administration&#xD;
      Secondary endpoints: Absence of vector related adverse reactions 24 months after vector&#xD;
      administration. Demonstration of improved retinal anatomy and/or visual function other than&#xD;
      best corrected visual acuity in treated eye compared to the untreated control eye 24 months&#xD;
      after vector administration.&#xD;
&#xD;
      Statistical methods:&#xD;
&#xD;
      Summary statistics will be presented for both eyes (Treated Eye versus Control Eye groups).&#xD;
      No formal statistical comparison will be performed (no p-value will be computed). For&#xD;
      categorical/binary data, the number and proportion of patients in each category will be&#xD;
      presented with its 95% Confidence Interval (CI). For continuous data, mean (and its 95% CI)&#xD;
      and Standard Deviation (SD) will be presented.&#xD;
&#xD;
      The primary outcome measure will be the proportion of patients with a relative change from&#xD;
      baseline of &gt; 5 in ETDRS letters (treated vs. untreated eye, change from BL). At each time&#xD;
      point, the change from baseline in ETDRS letters will be computed for each eye. The mean&#xD;
      change from baseline in ETDRS letters will be presented for both the treated eye and the&#xD;
      control eye groups.&#xD;
&#xD;
      At each time point, the change from baseline and the percentage change from baseline in the&#xD;
      area of autofluoresence will be computed for each eye and their mean will be presented for&#xD;
      both the treated eye and the control eye groups.&#xD;
&#xD;
      With regards to microperimetry, at each time point, the change from baseline in mean&#xD;
      sensitivity will be computed for each eye. The mean change from baseline in mean sensitivity&#xD;
      will be presented for both the treated eye and the control eye groups.&#xD;
&#xD;
      Adverse events will be listed. Other Investigator Sponsored Studies are expected to be run&#xD;
      with a similar protocol for the same indication and with the same intervention. A&#xD;
      meta-analysis on the Investigator Sponsored studies is planned. A separate Statistical&#xD;
      Analysis Plan describing the details of the meta-analysis will be developed.&#xD;
&#xD;
      Timetable:&#xD;
&#xD;
      Planned trial period: 24 month Follow-up duration: 36 month&#xD;
&#xD;
      The end of trial is the date on which the last treated patient completes the tests of their&#xD;
      planned close-out visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>best corrected visual acuity in treated eye</measure>
    <time_frame>up to 24 months after vector administration</time_frame>
    <description>Change from baseline in best corrected visual acuity in treated eye, compared to untreated control eye up to 24 months after vector administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of vector-related adverse reactions</measure>
    <time_frame>24 months after vector administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fundus autofluorescence analysis</measure>
    <time_frame>24 months after vector administration</time_frame>
    <description>improved retinal anatomy in treated eye compared to the untreated control eye 24 months after vector administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central visual field using microperimetry readings</measure>
    <time_frame>24 months after vector administration</time_frame>
    <description>improved visual function in treated eye compared to the untreated control eye 24 months after vector administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contrast sensitivity</measure>
    <time_frame>24 months after vector administration</time_frame>
    <description>improved visual function other than best corrected visual acuity in treated eye compared to the untreated control eye 24 months after vector administration (scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>colour vision</measure>
    <time_frame>24 months after vector administration</time_frame>
    <description>improved visual function other than best corrected visual acuity in treated eye compared to the untreated control eye 24 months after vector administration (physiological parameter)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Choroideremia</condition>
  <arm_group>
    <arm_group_label>open label injection of rAAV2.REP1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label, single arm interventional trial with subretinal injection of rAAV2.REP1 and fellow eye comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>rAAV2.REP1</intervention_name>
    <description>single subretinal injection</description>
    <arm_group_label>open label injection of rAAV2.REP1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is willing and able to give informed consent for participation in the&#xD;
             study.&#xD;
&#xD;
          2. Male aged 18 years or above.&#xD;
&#xD;
          3. Genetically confirmed diagnosis of choroideremia. Patients without a confirmed&#xD;
             mutation in the CHM gene, but who have the clinical phenotype typical of choroideremia&#xD;
             can only be enrolled if they meet all the following three criteria: (i) family history&#xD;
             consistent with X-linked inheritance, (ii) absent REP1 protein on Western blot of a&#xD;
             blood sample and, (iii) normal RPE65 gene on sequencing.&#xD;
&#xD;
          4. Active disease visible clinically within the macula region&#xD;
&#xD;
          5. Best-corrected visual acuity equal to or worse than 6/9 (20/32; Decimal 0.63; LogMAR&#xD;
             0.2) but better than or equal to 6/60 (20/200; Decimal 0.1; LogMAR 1.0) in the study&#xD;
             eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female and child participants (under the age of 18)&#xD;
&#xD;
          2. Participants with a history of amblyopia in the study eye&#xD;
&#xD;
          3. Men unwilling to use barrier contraception methods, if relevant&#xD;
&#xD;
          4. Absence of quantifiable visual function in the fellow eye or other ocular morbidity&#xD;
             which might confound use of the fellow eye as a long-term control.&#xD;
&#xD;
          5. Any other significant ocular and non-ocular disease/disorder or retinal surgery which,&#xD;
             in the opinion of the Investigator, may either put the participants at risk because of&#xD;
             participation in the study, or may influence the results of the study, or the&#xD;
             participant's ability to participate in the study. This would include not taking or&#xD;
             having a contraindication to oral prednisolone, such as a history of gastric ulcer or&#xD;
             significant side effects.&#xD;
&#xD;
          6. Participants who have participated in another research study involving an&#xD;
             investigational product in the past 12 weeks, or having had gene or cellular therapy&#xD;
             at any time prior to this study.&#xD;
&#xD;
          7. Patients with amblyopic eyes should be excluded in general, since the evaluation of&#xD;
             the primary endpoint presupposes the ability to fixate both eyes&#xD;
&#xD;
          8. Prior intraocular surgery within six months&#xD;
&#xD;
          9. Intolerance to local anesthesia and/or contraindication to IVT surgery (anemia&#xD;
             Hb&lt;8g/dl, severe cardiovascular disease, severe coagulopathy, etc.)&#xD;
&#xD;
         10. High fever or high fever disease, patients with a history of autoimmune conditions/&#xD;
             other systemic diseases that may have ocular manifestations (e.g. sarcoidosis) or&#xD;
             neurodegenerative conditions (e.g. multiple sclerosis, neuromyelitis optica,&#xD;
             Parkinson's disease)&#xD;
&#xD;
         11. Patients suffering from other genetic mutations leading to pathological retinal&#xD;
             conditions&#xD;
&#xD;
         12. Patients treated by oral corticoids within 14 days prior inclusion at the study entry&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel D Fischer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Ophthalmology, University Hospital T端bingen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Tuebingen, Center for Ophthalmology</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <keyword>hereditary retinal degeneration</keyword>
  <keyword>rAAV2.REP1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

